Pfizer, Inc. (NYSE: PFE) receives approval from the U.S. Food and Drug Administration (FDA)


Dallas, Texas 07/15/2013 (Financialstrend) – Pfizer, Inc. (NYSE:PFE)  obtained approval from the U.S. Food and Drug Administration (FDA) for the company’s Eliquis® (apixaban), a Factor Xa inhibitor, which is used to prevent venous thromboembolic events (VTE) in adult patients for those who had undergone surgery related to elective hip or knee replacement. Recently, the results of the AMPLIFY (6-month trial) 3rd phase were announced. The trial involved 5,395 patients with acute PE (pulmonary embolism) and/or VTE (venous thromboembolism) which includes symptomatic DVT (deep vein thrombosis). In this examination, the company achieved the initial efficacy of non inferiority to reduce the composite endpoint of VTE-related death or VTE, to the care current standard.

 Pfizer Inc (NYSE:PFE) also obtained approval for its pneumococcal conjugate vaccine in Europe and thereby this vaccine can be used by a wider age group. Prevenar 13 is the name of the vaccine released by Pfizer Inc (NYSE:PFE) and the recent approval concerns usage of this vaccine expansion for adults aged from 18 to 49 years. In the European Union, the drug was previously approved for humans aged from six weeks to 17 years old, as well as for adults of more than 50 years old. The report “Pfizer Inc. – Product Pipeline Review – 2013” was released by Global Market Direct, and provides data of research and development of Pfizer Inc (NYSE:PFE ), and involves information of dormant projects, features on discontinued projects, complete with latest updates and current developmental pipeline.

Pfizer Inc. (NYSE:PFE) shares currently trading at $28.73, down by 0.28%. During the day, the stock was fluctuating between a low intraday price of $28.52 and a high intraday price of $28.84 per share. The stock currently has a 52-week low of $22.70 and a 52-week high of $31.15 per share. Pfizer currently has a market cap of $203.79 billion with around 7.09 billion outstanding shares in the market and institutional ownership of 74 percent of its total equity capital. The stock witnessed active trading in around 29.25 million shares on Friday, while the average level of trading activity for the stock stood at 88.09 million shares per day.